Manfred Welslau

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 439 citations · Full text

Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.

Kimberly Blackwell, David Miles, Luca Gianni et al. · Journal of Clinical Oncology · 2012 · 83 citations

Breast Oncology, Cancer Management, Pathology +17

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 44 citations

Hematological Malignancy, Oncology, Transplantation +8

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

Christian Kollmannsberger, Oliver Rick, Holger Klaproth et al. · British Journal of Cancer · 2002 · 30 citations · Full text

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Lena Weiss, Meinolf Karthaus, Jorge Riera‐Knorrenschild et al. · ESMO Open · 2022 · 17 citations · Full text